Month: January 2019

BUHLMANN Diagnostics Corp Announces New Distribution Agreement with Meridian Biosciences, Inc.

BUHLMANN Diagnostic Corp (BDC), Amherst, NH is proud to announce they have entered into a distribution agreement with Meridian Bioscience, Inc., Cincinnati, Ohio to market the FDA-cleared BÜHLMANN fCAL® ELISA for the quantitative measurement of fecal calprotectin in human stool. The BÜHLMANN fCAL® ELISA aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn’s

Two New fCAL turbo Video Testimonials from Portugal

BÜHLMANN fCAL® turbo is for Research Use Only in the US. Not to be used in diagnostic procedures. Health Canada License: 96808 Unilabs Portugal, a private European lab chain, made a comprehensive evaluation of different Calprotectin assays on the market and found many discrepancies with assays from other suppliers. Finally, they chose the BÜHLMANN fCAL® turbo simply because it

BÜHLMANN Laboratories AG (BL), based in Basel Switzerland, has been discovering, developing & manufacturing innovative chemistry and immunological in-vitro diagnostic (IVD) and research use only (RUO) assays for almost 50 years (circa 1976). As the United States commercial affiliate of BL, BUHLMANN Diagnostics Corp (BDC), based in Amherst, NH is committed to providing exceptional sales, support, and technical services to our clinical, discovery and basic science research laboratory customers.

Month: January 2019

BUHLMANN Diagnostics Corp Announces New Distribution Agreement with Meridian Biosciences, Inc.

Two New fCAL turbo Video Testimonials from Portugal

ABOUT US

SOCIAL MEDIA

QUICK LINKS

CONTACT US